Optimum’s clients hit the ground running after Easter break

It was a short week after the Easter break but there was plenty of positive news from Optimum’s clients with summer just around the corner. 

Novo Holdings Asia Investment on the up 

Novo Holdings’ Asia Investments team on Wednesday published its annual review – a year of developing and building for long-term results. 

During 2023, the unit added three new portfolio companies and its existing portfolio companies continued to grow. 

Precision Oncology Innovator SimBioSys and General Inception Announced a Strategic Partnership to Accelerate Cancer Drug Development 

SimBioSys, a leading innovator in precision oncology, and General Inception, a global company igniter, announced on Wednesday a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modelling to better understand unique tumour spatial biophysical characteristics. 

PhenoScope, SimBioSys’ powerful proprietary technology and service, can analyse vast fields of multi-modal data seamlessly, generating novel insights, including unique spatial biophysical insights in a 4-dimension space, for cancer drug discovery and development which are not apparent by looking at one type of data alone.  

REDUCED secures EUR 6 million financing led by Novo Holdings to scale its natural food ingredients business 

REDUCED, a Copenhagen-based company that uses fermentation technology to transform food and agriculture industry side streams into natural food ingredients, on Thursday announced it has secured EUR 6 million in new financing 

The funds were raised from a range of investors, including new investment from Novo Holdings and the Nordic flavour house Einar Willumsen, as well as existing investors EIFO and Rockstart Agrifood. 

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024 

Antibody-drug conjugate (ADC) specialist Adcendo ApS  announced on Thursday that it will be presenting data on the expression of its novel ADC target uPARAP and the in vitro and in vivo activity of a uPARAP targeting ADC in glioblastoma multiforme (GBM) at the American Association for Cancer Research (AACR) Annual Meeting. The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark. 

Data demonstrate that uPARAP is highly expressed in tumour samples obtained from glioblastoma multiforme patients and that uPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumour activity in a glioblastoma multiforme PDX model. The new data provides evidence that uPARAP targeting ADCs are a potential novel treatment option for glioblastoma multiforme patients. 

Ariceum Therapeutics to present new radioligand therapy data at AACR 

Radiopharmaceuticals biotech Ariceum Therapeutics on Thursday said it will be presenting a poster at AACR. 

The poster, in collaboration with research partner and global pharma company UCB, demonstrates the discovery of novel macrocyclic peptide radioligands for tumour therapy by UCB’s mRNA display platform, ExtremeDiversity™ and its potential for fast and efficient discovery of highly specific macrocyclic peptides with optimal binding properties suitable for RLT. 

Heidelberg Pharma to host R&D Webinar following novel data presented at AACR 

Heidelberg Pharma AG, a clinical stage biotech company developing innovative ADCs, on Friday announced that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media following presentation of novel data at AACR. 

The event will provide information on Heidelberg Pharma’s lead clinical ATAC product candidate HDP-101 targeting relapsed and refractory multiple myeloma as well as its proprietary ADC toolbox and therapeutic product pipeline. It will include a clinical presentation of first efficacy data from the Phase I/IIa clinical trial.